A Prospective Open-Label Extension Study of Gaboxadol in Primary Insomnia

Lundbeck

Status and phase: Completed; Phase 3

Conditions: Primary Insomnia

Treatments: Drug: Gaboxadol

Study type: Interventional

Funder types: Industry

Identifiers

NCT00209950

10440

Details and patient eligibility

About

To evaluate the safety and tolerability of gaboxadol in primary insomnia

Full description

To evaluate long-term safety of gaboxadol in healthy adults.

Sex: All

Ages: 18 to 65 years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria:

• patients with a diagnosis of primary insomnia

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Single Group Assignment

Masking: None (Open label)